Open AccessEnhanced Ehrlich tumor inhibition using DOX-NP™ and gold nanoparticles loaded liposomes
Author(s) -
Mohsen M. Mady,
Fatima Hasan Al-Shaikh,
Faridah Farhan Al-Farhan,
Anwar A. Aly,
Mai Almohanna,
M. M. Ghannam
Publication year - 2016
Publication title -
aip conference proceedings
Language(s) - English
Resource type - Conference proceedings
eISSN - 1551-7616
pISSN - 0094-243X
DOI - 10.1063/1.4945969
Subject(s) - doxorubicin , liposome , ehrlich ascites carcinoma , pharmacology , colloidal gold , tolerability , chemistry , toxicity , nanoparticle , chemotherapy , materials science , nanotechnology , medicine , in vitro , biochemistry , adverse effect , surgery , organic chemistry
Treatment with doxorubicin (DOX) is a common treatment for different types of cancer. DOX-NP is one of a well established marketed liposomal formulation for DOX. It has advantages over free DOX in reducing the cardiac toxicity and increasing the efficacy. Gold nanoparticles (GNPs), have been widely used in biomedical applications such as medical imaging and biosensors. Mice bearing Ehrlich tumor were injected with saline, free doxorubicin (DOX) in solution, gold nanoparticles loaded liposomes and commercial liposomal encapsulated doxorubicin (DOX-NP). The results showed that GNPs loaded liposomes could enhance the antitumor activity of commercial liposomal formulation (DOX-NP) and displayed significantly decreased systemic toxicity compared with free DOX and commercial liposomal formulation (DOX-NP) at the equivalent dose. So the injection of GNPs and DOX-NP is expected to increase the cell killing and make it a promising approach to cancer treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom